One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Codexis logo
Codexis CDXS
$ 1.24 5.43%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

Codexis Cash Flow 2025-2008 | CDXS

Brief overview of Codexis's cash movements

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

Operating cash flow is negative at -$19.4 million, leaving internal funding capacity weak.

Only 1 of five observations were above zero. The business relies heavily on individual strong periods.

Operating cash margin decreased to -27.5% from -13.6% initially. The quality of receipts deteriorated.

Conclusion

Codexis's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.

Annual Cash Flow Codexis

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Operating Cash Flow

-19.4 M -49.4 M -52.6 M 11.3 M -14.3 M -16.5 M -12.6 M -14.1 M -8.76 M -1.86 M -433 K 321 K -23 M -11.9 M -490 K -16.4 M -8.79 M -

Depreciation & Amortization

5.25 M 4.95 M 5.52 M 5.4 M 3.11 M 1.95 M 1.57 M 1.15 M 1.04 M 1.73 M 3.37 M 3.37 M 3.37 M 3.51 M 3.72 M 1.06 M 957 K -

Accounts Payables

1.55 M 2.84 M 5.95 M 3.25 M 3 M 2.97 M 2.62 M 3.05 M 3.54 M 4.23 M 3.4 M 4.67 M 3.96 M 3.65 M 10.4 M 9.21 M - -

Accounts Receivables

- - 10 M 31.9 M 25 M 13.9 M 9.03 M 11.6 M 11.8 M 5.92 M 7.33 M 3.87 M 5.41 M 7.54 M 18.9 M 15.3 M - -

Total Inventories

1.82 M 1.8 M 2.68 M 2.03 M 1.16 M 964 K 371 K 589 K 1.04 M 825 K 992 K 1.4 M 1.49 M 1.3 M 4.49 M 2.82 M - -

All numbers in USD currency

Quarterly Cash Flow Codexis

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -13.2 M - - - -13.8 M - - - -7.79 M - - - -9.21 M - 6.37 M - -11.2 M - -14.9 M - -6.44 M - -15 M -11.5 M -1.42 M - -8.9 M -7.91 M -2.85 M - -13.4 M -12.1 M -4.18 M - -16.4 M -11.5 M -3.57 M - -7.02 M 187 K 219 K - -7.59 M -8.02 M -3.85 M - -4.65 M -6.34 M -2.4 M - -19.1 M -10.6 M -3.49 M - -7.16 M -3.29 M 593 K - 2.41 M -343 K 7.29 M

Depreciation & Amortization

1.3 M 1.29 M - 1.32 M 1.3 M 1.2 M - 1.18 M 1.24 M 1.25 M - 1.36 M 1.48 M 1.47 M - 1.4 M 1.34 M 1.22 M - 768 K 716 K 659 K - 503 K 462 K 438 K - 1.12 M 693 K 319 K - 812 K 503 K 238 K - 795 K 554 K 326 K - 1.36 M 924 K 465 K - 1.57 M 1.08 M 558 K - 2.68 M 2.08 M 1.02 M - 5.31 M 3.54 M 1.8 M - 6.82 M 4.54 M 2.2 M - 2.79 M 1.86 M 941 K

Accounts Payables

1.55 M 2.13 M 2.84 M 2.42 M 1.47 M 6.05 M 2.84 M 4.21 M 3.68 M 3.46 M 5.95 M 3.1 M 4.04 M 4.49 M 3.25 M 2.62 M - 1.95 M 3 M 3.28 M 3.16 M 3.57 M 2.97 M 2.97 M 2.97 M 2.97 M 2.62 M 2.62 M 2.62 M 2.62 M 3.05 M 3.05 M 3.05 M 3.05 M 3.54 M 3.54 M 3.54 M 3.54 M 4.23 M 4.23 M 4.23 M 4.23 M 3.4 M 3.4 M 3.4 M 3.4 M 4.67 M 4.67 M 4.67 M 4.67 M 3.96 M 3.96 M 3.96 M 3.96 M 3.65 M 3.65 M 3.65 M 3.65 M 10.4 M 10.4 M 10.4 M 10.4 M

Accounts Receivables

- - - - - - - - - - - - - - - - - - 25 M - - - 13.9 M - - - 9.06 M 12.3 M 11.8 M 12.6 M 11.6 M 11.6 M 11.6 M 11.6 M 11.4 M 11.8 M 11.8 M 11.8 M 5.92 M 5.92 M 5.92 M 5.92 M 7.33 M 7.33 M 7.33 M 7.33 M 3.87 M 3.87 M 3.87 M 3.87 M 5.41 M 5.41 M 5.41 M 5.41 M 7.54 M 7.54 M 7.54 M 7.54 M 18.9 M 18.9 M 18.9 M 18.9 M

Total Inventories

1.82 M 2 M 1.8 M 1.94 M 1.94 M 1.78 M 1.8 M 2.1 M 2.23 M 2.44 M 2.68 M 2.3 M 2.05 M 2 M 2.03 M 1.62 M - 1.56 M 1.16 M 1.08 M 1.08 M 1.03 M 964 K 964 K 964 K 964 K 371 K 371 K 371 K 371 K 589 K 589 K 589 K 589 K 1.04 M 1.04 M 1.04 M 1.04 M 825 K 825 K 825 K 825 K 992 K 992 K 992 K 992 K 1.4 M 1.4 M 1.4 M 1.4 M 1.49 M 1.49 M 1.49 M 1.49 M 1.3 M 1.3 M 1.3 M 1.3 M 4.49 M 4.49 M 4.49 M 4.49 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Codexis, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 2.91 9.81 % $ 25.1 M usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 145.95 0.52 % $ 365 B usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.04 13.04 % $ 15.9 M usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 6.79 7.94 % $ 980 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.43 6.65 % $ 235 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 19.12 2.39 % $ 3.22 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 2.37 0.83 % $ 13 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 135.71 0.68 % $ 13.5 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 231.83 0.11 % $ 30.4 B usaUSA
NuCana plc NuCana plc
NCNA
$ 0.99 0.98 % $ 11.1 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.0 0.15 % $ 657 M britainBritain
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.58 2.27 % $ 3.79 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 46.61 4.37 % $ 1.35 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 19.98 2.17 % $ 286 M usaUSA
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.35 2.98 % $ 19.9 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 10.34 1.35 % $ 283 M israelIsrael
argenx SE argenx SE
ARGX
$ 819.14 3.42 % $ 50.2 B niderlandNiderland
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 59.75 0.12 % $ 122 B usaUSA
Nkarta Nkarta
NKTX
$ 1.8 1.35 % $ 133 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 1.41 0.5 % $ 142 M usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.28 8.07 % $ 314 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Novavax Novavax
NVAX
$ 11.26 1.42 % $ 1.82 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 38.83 0.14 % $ 173 B danmarkDanmark
Novartis AG Novartis AG
NVS
$ 150.62 0.16 % $ 292 B schweizSchweiz
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 9.18 2.64 % $ 115 M usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 6.87 2.5 % $ 1.29 B usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 6.58 1.03 % $ 572 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.51 0.72 % $ 2.22 B canadaCanada
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.32 0.11 % $ 352 M usaUSA